Ending COVID/Post Vaccination/Briefing on Covid Vaccines in Developmental Stages

 Ending COVID/Post Vaccination/Preliminary Draft of Vaccine Candidates in Trials

Name of Vaccine	Type	Company	Country	Clinical Trials
CoronaVac  PiCoVacc	Inactivated  Vaccine	Sinovac  Biotech	China	China Phase III India Phase III Kazakhstan Phase III China Phase I China Phase II
CodaVax-COVID	Live Attenuated	Codagenix	USA/India	England Phase I
Novavax  NVX-CoV2373	Recombinant Protein Vaccine	Medicago	USA	England Phase III Mexico Phase III USA Phase III South Africa Phase IIb
ChAdOx1 nCoV-19 Ad-26 COV2.S COVID-19	Replication Incompetent Vector	Janssen Johnson & Johnson’s	USA	ENSEMBLE Trial I Phase III Argentina/Brazil/Chile/ Peru/South Africa Trial II Phase III England/France/Germany/Spain/Belgium/ Philippines
(Ad 5) Adenovirus type5 Ad5-vectored COVID-19 5x10^10 viral particles	Replication  Incompetent Vector	CanSino	China	China Phase II Mexico Phase III
( rAd5) vector based  prime boost COVID-19 (rAd26) vector based	Replication  Incompetent Vector	Gamaleya Research Institute	Russia	Russia Phase I Russia Phase II
GRAd-COV2  Replication defective  adenoviral vector	Replication  Incompetent Vector	ReiThera	Italy	Italy Phase I
TMV-083 MV-SARS-CoV-2	Replication  Incompetent Vector	Institute Pasteur	France	France  Belgium